/

Società

TR

Non verificato

TRANSGÈNE

Di cosa scriviamo

Ecologia/Salute ambientalePolitica InternaSerie/film/TVServizi e spazi pubbliciWeb e Social Network

149 comunicati stampa

Guarda tutti i comunicati

04/05/2026

Arte

Cultura

Musica

Legge/Diritto

Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026 - transgene

Fonte

1.00

0

29/04/2026

Arte

Cultura

Musica

Legge/Diritto

Transgene Provides Business and Financial Update for Q1 2026 - transgene

Fonte

1.00

0

28/04/2026

Arte

Cultura

Musica

Legge/Diritto

First Quarter 2026 Financial Results - transgene

Fonte

1.00

0

26/04/2026

Web e Social Network

Software

Politica Interna

Sicurezza delle informazioni

Synthetic Genome Shuffling of Poxviruses via Yeast TAR Cloning for Next-Generation Oncolytic Platforms - transgene

Fonte

1.00

0

13/04/2026

Arte

Cultura

Musica

Legge/Diritto

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer - transgene

Fonte

1.00

0

07/04/2026

Arte

Cultura

Musica

Legge/Diritto

Transgene to Participate in Upcoming Investor Meetings - transgene

Fonte

1.00

0

02/04/2026

Arte

Cultura

Musica

Legge/Diritto

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer - transgene

Fonte

1.00

0

01/04/2026

Web e Social Network

Software

Sport

TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment - transgene

Fonte

1.00

0

26/03/2026

Arte

Cultura

Musica

Legge/Diritto

Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress - transgene

Fonte

1.00

0

24/03/2026

Arte

Cultura

Musica

Legge/Diritto

2025 Full-year results and business update - transgene

Fonte

1.00

0

Seguaci

0

Compatibilità

0